Mark Claus, MD
Allergy · Brockton, MANPI 1518910686
Payments from drug & device makers
Across 633 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- GSK$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$806
- Teva Pharmaceuticals USA, Inc.$400
- Novartis$382
- plus $4K from 32 others
What the payments were for
- Food & beverage$13,03399%
- Education$1371%
- Gifts$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 192 | $4,683 |
| GSK | 117 | $1,887 |
| Sanofi | 43 | $1,105 |
| Regeneron Healthcare Solutions, Inc. | 38 | $806 |
| Teva Pharmaceuticals USA, Inc. | 24 | $400 |
| Novartis | 22 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $368 |
| Boehringer Ingelheim | 16 | $331 |
| Amgen | 16 | $291 |
| Blueprint Medicines Corporation | 9 | $269 |
| Genentech USA, Inc. | 18 | $261 |
| Octapharma USA, Inc. | 11 | $246 |
| Pharming Healthcare, Inc. | 10 | $242 |
| Kaleo, Inc. | 12 | $226 |
| Grifols USA, LLC | 10 | $210 |
| Pfizer | 10 | $196 |
| CSL Behring | 8 | $192 |
| Covis Pharma GmbH | 7 | $114 |
| GC Biopharma USA, Inc. | 4 | $112 |
| AbbVie | 5 | $106 |
| Aimmune Therapeutics, Inc. | 5 | $101 |
| Biocryst US Sales Co., LLC | 4 | $97 |
| Lilly USA, LLC | 3 | $91 |
| Alk-abello, Inc | 5 | $77 |
| Mylan Specialty L.p. | 4 | $57 |
| Verona Pharma, Inc. | 3 | $51 |
| Incyte Corporation | 2 | $49 |
| Organon | 2 | $45 |
| X4 Pharmaceuticals, Inc. | 1 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Invivyd Inc | 1 | $21 |
| Merck | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Purelife, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,181 in reported general payments places this provider in the 90th percentile of 21 allergy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 40 | $147,640 |
| Dupixent PenDupilumab | 33 | $130,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $119,117 |
| XolairOmalizumab | 33 | $81,288 |
| Spiriva RespimatTiotropium Bromide | 72 | $79,275 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $78,017 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $73,976 |
| Fasenra PenBenralizumab | 11 | $66,044 |
| Incruse ElliptaUmeclidinium Bromide | 85 | $43,129 |
| Arnuity ElliptaFluticasone Furoate | 72 | $30,500 |
| Epinephrine | 100 | $17,894 |
| DuleraMometasone/Formoterol | 26 | $14,577 |
| Wixela InhubFluticasone Propion/Salmeterol | 58 | $13,564 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 319 | $12,560 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $11,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,887 | $270,764381 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $4,683 | $86,38498 claims |
| Boehringer IngelheimSpiriva Respimat | $331 | $79,27572 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $17,894100 claims |
| MerckDulera | $18 | $14,57726 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $400 | $11,79622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 allergy providers in Massachusetts.
Other allergy in Brockton
- Michael LawrenceBrockton$11K
- Ralph CahalyMilford$30K
- John SaryanBurlington$15K
- Margaret Vallen MashikianSouth Weymouth$9K
- Priyal AminWestford$3K
- Li LiangChelmsford$2K
- Bryan StoneLawrence$2K
- Fuad MudawwarFlorence$2K
- Frank TwarogConcord$1K
- Stuart RheinFramingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.